GLP-1 vs Metformin in Prediabetes: 256,492-Patient Data Reshape Peptide Therapy Debate
A 256,492-patient retrospective analysis associates GLP-1 receptor agonists with lower diabetes and death risk than metformin in prediabetes, with caveats for peptide therapy clinics.